Brian D. Crompton

8.8k total citations
57 papers, 1.2k citations indexed

About

Brian D. Crompton is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research and Molecular Biology. According to data from OpenAlex, Brian D. Crompton has authored 57 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pulmonary and Respiratory Medicine, 30 papers in Cancer Research and 17 papers in Molecular Biology. Recurrent topics in Brian D. Crompton's work include Sarcoma Diagnosis and Treatment (33 papers), Cancer Genomics and Diagnostics (27 papers) and Neuroblastoma Research and Treatments (13 papers). Brian D. Crompton is often cited by papers focused on Sarcoma Diagnosis and Treatment (33 papers), Cancer Genomics and Diagnostics (27 papers) and Neuroblastoma Research and Treatments (13 papers). Brian D. Crompton collaborates with scholars based in United States, Canada and France. Brian D. Crompton's co-authors include Steven G. DuBois, Katherine A. Janeway, Kimberly Stegmaier, David S. Shulman, Aaron R. Thorner, Kelly Klega, Anwesha Nag, AeRang Kim, Julia Glade Bender and Stephanie Meyer and has published in prestigious journals such as Science, Nucleic Acids Research and Journal of Clinical Investigation.

In The Last Decade

Brian D. Crompton

56 papers receiving 1.1k citations

Peers

Brian D. Crompton

PRM

ONCOL

NEURO

Carsten Grüllich Germany

Joanne Rutgers United States

Barbara De Moerloose Belgium

Susanne A. Gatz United Kingdom

Yoshihiro Kameoka Japan

Diana Romero United States

Beihua Kong China

Lionel D’Hondt Belgium

Erin M. Bertino United States

Vamsi Kota United States

Carsten Grüllich Germany

Brian D. Crompton

557 ×1.1

479 ×0.9

PRM

188 ×0.5

493 ×1.5

ONCOL

53 ×0.4

NEURO

Citations per year, relative to Brian D. Crompton Brian D. Crompton (= 1×) peers Carsten Grüllich

Countries citing papers authored by Brian D. Crompton

Since Specialization

Citations

This map shows the geographic impact of Brian D. Crompton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian D. Crompton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian D. Crompton more than expected).

Fields of papers citing papers by Brian D. Crompton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian D. Crompton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian D. Crompton. The network helps show where Brian D. Crompton may publish in the future.

Co-authorship network of co-authors of Brian D. Crompton

This figure shows the co-authorship network connecting the top 25 collaborators of Brian D. Crompton. A scholar is included among the top collaborators of Brian D. Crompton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian D. Crompton. Brian D. Crompton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shulman, David S., Kelly Klega, Nan Chen, et al.. (2024). Prospective evaluation of pre-treatment ctDNA burden in localized osteosarcoma to identify patients with inferior outcomes: A report from the LEOPARD study.. Journal of Clinical Oncology. 42(16_suppl). 11510–11510. 1 indexed citations

Shulman, David S., Kelly Klega, Allen Buxton, et al.. (2024). Association of elevated ctDNA burden following one cycle of chemotherapy with inferior outcomes for patients with metastatic Ewing sarcoma: A report from the Children’s Oncology Group (COG).. Journal of Clinical Oncology. 42(16_suppl). 10018–10018. 1 indexed citations

Grohar, Patrick J., Karla V. Ballman, Leo Mascarenhas, et al.. (2024). SARC037: Phase II results of trabectedin given as a 1-hour (h) infusion in combination with low dose irinotecan in patients (pts) with relapsed/refractory Ewing sarcoma (ES).. Journal of Clinical Oncology. 42(16_suppl). 11508–11508. 5 indexed citations

Shulman, David S., Kelly Klega, Mark Krailo, et al.. (2024). Molecular characterization of patients with localized Ewing sarcoma targeting discrete prognostic groups: A report from the Children’s Oncology Group.. Journal of Clinical Oncology. 42(16_suppl). 11509–11509. 1 indexed citations

Laetsch, Theodore W., Stephan D. Voss, Kathleen Ludwig, et al.. (2024). Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion–Positive Solid Tumors (Children's Oncology Group ADVL1823). Journal of Clinical Oncology. 43(10). 1188–1197. 4 indexed citations

Shulman, David S., Priscilla Merriam, Edwin Choy, et al.. (2023). Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma. Cancer Medicine. 12(14). 15207–15216. 21 indexed citations

Campbell, Kevin, Nan Chen, Kerri L. Cavanaugh, et al.. (2023). Phase 1 study of cabozantinib in combination with topotecan–cyclophosphamide for patients with relapsed Ewing sarcoma or osteosarcoma. Pediatric Blood & Cancer. 70(12). e30681–e30681. 3 indexed citations

Abbou, Samuel, Kelly Klega, Junko Tsuji, et al.. (2023). Circulating Tumor DNA Is Prognostic in Intermediate-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. Journal of Clinical Oncology. 41(13). 2382–2393. 16 indexed citations

Walz, Amy L., Mariana Maschietto, Brian D. Crompton, et al.. (2023). Tumor biology, biomarkers, and liquid biopsy in pediatric renal tumors. Pediatric Blood & Cancer. 70(S2). e30130–e30130. 9 indexed citations

10.

Madanat‐Harjuoja, Laura, Kelly Klega, Yao Lu, et al.. (2022). Circulating Tumor DNA Is Associated with Response and Survival in Patients with Advanced Leiomyosarcoma. Clinical Cancer Research. 28(12). 2579–2586. 12 indexed citations

11.

Allen‐Rhoades, Wendy, Leo Mascarenhas, Wei Xue, et al.. (2022). ARST2031: A study to compare early use of vinorelbine and maintenance therapy for patients with high risk rhabdomyosarcoma.. Journal of Clinical Oncology. 40(16_suppl). TPS11591–TPS11591. 5 indexed citations

12.

Hemming, Matthew L., Patrick Bhola, Leona A. Doyle, et al.. (2022). Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression. Clinical Cancer Research. 28(11). 2397–2408. 6 indexed citations

13.

Hingorani, Pooja, Mark Krailo, Allen Buxton, et al.. (2022). Phase 2 study of anti-disialoganglioside antibody, dinutuximab, in combination with GM-CSF in patients with recurrent osteosarcoma: A report from the Children's Oncology Group. European Journal of Cancer. 172. 264–275. 23 indexed citations

14.

Madanat‐Harjuoja, Laura, Lindsay A. Renfro, Kelly Klega, et al.. (2022). Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533. Journal of Clinical Oncology. 40(26). 3047–3056. 18 indexed citations

15.

Camp, Sabrina Y., Seunghun Han, Erin L. Young, et al.. (2022). Germline predisposition to pediatric Ewing sarcoma is characterized by inherited pathogenic variants in DNA damage repair genes. The American Journal of Human Genetics. 109(6). 1026–1037. 27 indexed citations

16.

Abbou, Samuel, David S. Shulman, Steven G. DuBois, & Brian D. Crompton. (2019). Assessment of circulating tumor DNA in pediatric solid tumors: The promise of liquid biopsies. Pediatric Blood & Cancer. 66(5). e27595–e27595. 40 indexed citations

17.

Roberts, Ryan D., Michael M. Lizardo, Damon R. Reed, et al.. (2019). Provocative questions in osteosarcoma basic and translational biology: A report from the Children's Oncology Group. Cancer. 125(20). 3514–3525. 87 indexed citations

18.

Pishas, Kathleen I., Christina D. Drenberg, Cenny Taslim, et al.. (2018). Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response. Molecular Cancer Therapeutics. 17(9). 1902–1916. 42 indexed citations

19.

Crompton, Brian D., Aaron R. Thorner, Amanda L. Christie, et al.. (2013). High-Throughput Tyrosine Kinase Activity Profiling Identifies FAK as a Candidate Therapeutic Target in Ewing Sarcoma. Cancer Research. 73(9). 2873–2883. 42 indexed citations

20.

Deller, D. J., et al.. (1964). Metabolic effects of partial gastrectomy with special reference to calcium and folic acid. Gut. 5(3). 225–229. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact